Iselin C E, Box J W, Vollmer R T, Layfield L J, Robertson J E, Paulson D F
Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Cancer. 1998 Dec 1;83(11):2353-60. doi: 10.1002/(sici)1097-0142(19981201)83:11<2353::aid-cncr15>3.0.co;2-l.
Few studies have compared the outcome of radical prostatectomy between African-American males (AAM) and white males, and the results of the few studies that have are conflicting. Therefore, the authors examined the impact of radical surgery on localized prostate carcinoma in both patient populations, and assessed whether stratification by pathologic extent of local disease would yield an equivalent outcome.
Prostate specific antigen (PSA) failure and carcinoma-associated death rates were assessed in 1319 patients (115 AAM and 1204 white males), 872 of whom had a pretreatment serum PSA level taken. The percent of prostate involved by tumor, tumor wet weight, and DNA ploidy status were available in 755, 522, and 638 patients, respectively.
AAM were diagnosed at an earlier age than white males (62.8 years vs. 65.4 years; P = 0.0001). The distribution of pathologic extent of local disease was similar in both races, and AAM had a statistically higher rate of tumors with a Gleason sum of 7-10 at surgery than white males (64% vs. 46%). Race did not play a role in the outcome of patients with organ-confined or specimen-confined tumors. However, in patients with positive surgical margins, the median time to PSA failure and the median carcinoma-associated survival were less in AAM compared with white males. Tumor volume was significantly larger in AAM compared with white males. After multivariate adjustment for the pathologic extent of local disease, tumor grade at surgery, preoperative PSA, tumor volume, and age, African-American race was not a significant prognostic indicator for carcinoma-associated death and PSA failure (P = 0.17 and 0.14, respectively).
The outcome of radical prostatectomy was similar in both racial groups, although AAM with positive surgical margins tended to fail earlier than white males, suggesting greater biologic aggressiveness of residual disease. Because local extent of disease impacts on PSA failure and survival, and because the disease appears to present earlier in AAM, the AAM population may benefit from early detection programs.
很少有研究比较非裔美国男性(AAM)和白人男性接受根治性前列腺切除术的结果,少数相关研究的结果存在冲突。因此,作者研究了根治性手术对这两类患者群体中局限性前列腺癌的影响,并评估按局部疾病病理范围进行分层是否会产生相同的结果。
评估了1319例患者(115例AAM和1204例白人男性)的前列腺特异性抗原(PSA)失败率和癌相关死亡率,其中872例患者术前检测了血清PSA水平。分别有755例、522例和638例患者可获得肿瘤累及前列腺的百分比、肿瘤湿重和DNA倍体状态信息。
AAM的诊断年龄早于白人男性(62.8岁对65.4岁;P = 0.0001)。两个种族局部疾病的病理范围分布相似,且AAM手术时Gleason评分总和为7 - 10的肿瘤发生率在统计学上高于白人男性(64%对46%)。种族对器官局限性或标本局限性肿瘤患者的预后无影响。然而,手术切缘阳性的患者中,AAM的PSA失败中位时间和癌相关生存中位时间均短于白人男性。AAM的肿瘤体积显著大于白人男性。在对局部疾病病理范围、手术时肿瘤分级、术前PSA、肿瘤体积和年龄进行多因素调整后,非裔美国人种族并非癌相关死亡和PSA失败的显著预后指标(P分别为0.17和0.14)。
尽管手术切缘阳性的AAM比白人男性更早出现失败,但两个种族根治性前列腺切除术的结果相似,提示残留疾病具有更强的生物学侵袭性。由于局部疾病范围影响PSA失败和生存,且该疾病在AAM中似乎出现得更早,AAM人群可能从早期检测项目中获益。